老年心律失常患者采用参松养心胶囊与胺碘酮联合治疗的效果分析  

Effect Analysis of Shensong Yangxin Capsule Combined with Amiodarone in Elderly Patients with Arrhythmia

作　　者：熊丹东[1] XIONG Dandong(Fengcheng People’s Hospital,Yichun 336000,China)

机构地区：[1]江西省丰城市人民医院,江西宜春336000

出　　处：《中国伤残医学》2024年第24期65-68,共4页Chinese Journal of Trauma and Disability Medicine

摘　　要：目的:评估参松养心胶囊联合胺碘酮在老年心律失常患者中的疗效与安全性。方法:选取2022年2月—2024年4月丰城市人民医院收治的120例老年心律失常患者为研究对象,按随机数字表法将其分为对照组和研究组,各60例。对照组采用胺碘酮治疗,研究组采用参松养心胶囊联合胺碘酮治疗。两组均治疗4周。比较两组心功能指标、心脏指数(CI)及N末端脑钠肽前体(NT-proBNP)水平、不良反应发生情况。结果:治疗后,研究组左室射血分数高于对照组,左室舒张末期容积小于对照组,左心室舒张末期直径短于对照组、心力衰竭定量指标脑钠肽低于对照组,差异均有统计学意义(P<0.05)。治疗后,研究组CI及NT-proBNP水平均低于对照组,差异均有统计学意义(P<0.05)。研究组不良反应发生率为6.67%,低于对照组的8.33%,但差异无统计学意义(P>0.05)。结论:参松养心胶囊与胺碘酮联合治疗老年心律失常患者,可改善其心功能指标,降低CI和NT-proBNP水平,具有一定的用药安全性。Objective:To evaluate the efficacy and safety of Shensong Yangxin Capsule combined with Amiodarone in elderly patients with arrhythmia.Methods:A total of 120 elderly patients with arrhythmia admitted to Fengcheng People’s Hospital from February 2022 to April 2024 were selected as the study objects,and were divided into a control group and a study group according to random number table method,with 60 cases in each group.The control group was treated with Amiodarone,and the study group was treated with Shensong Yangxin Capsule combined with Amiodarone.Both groups were treated for 4 weeks.The cardiac function index(CI),the level of N-terminal brain natriuretic peptide precursor(NT-proBNP)and the occurrence of adverse reactions effects were compared between the two groups.Results:After treatment,the left ventricular ejection fraction of the study group was higher than that of the control group,the left ventricular end-diastolic volume was smaller than that of the control group,the left ventricular end-diastolic diameter was shorter than that of the control group,and the quantitative index of heart failure brain natriuretic peptide was lower than that of the control group,with statistical significance(P<0.05).After treatment,the levels of CI and NT-proBNP in the study group were lower than those in the control group,and the differences were statistically significant(P<0.05).The incidence of adverse reactions effects in the study group was 6.67%,which was lower than 8.33%in the control group,but the difference was not statistically significant(P>0.05).Conclusion:Shensong Yangxin Capsule combined with Amiodarone in the treatment of elderly patients with arrhythmia can improve the cardiac function index,reduce the level of CI and NT-proBNP,and has certain drug safety.

关 键 词：心律失常 老年 参松养心胶囊 胺碘酮 联合治疗 心脏功能 

分 类 号：R687.3[医药卫生—骨科学]